Tissue-resident macrophages (TRMs) play a continuous homeostatic role by phagocytosing short-lived neutrophils via efferocytosis, thereby limiting persistent inflammation and tissue damage. Work highlighted by Tan et al. and summarized here implicates the prostaglandin E2 receptor EP2 as a key regulator of TRM-mediated neutrophil clearance. In mouse models, age-associated declines in TRM number and phagocytic function were prevented by deleting EP2 in TRMs, while pharmacologic EP2 antagonism in aged animals produced similar restorative effects. Human data analyses supported increased EP2 expression in aged TRMs and concordant accumulation of senescent neutrophils, suggesting translational relevance.
TRMs are responsible for continual clearance of dying or short-lived neutrophils across organs. This efferocytosis maintains tissue homeostasis by preventing accrual of inflammatory debris and limiting chronic inflammatory signaling. With aging, the study reports a reduction in both TRM numbers and their phagocytic capacity in mice, a change that correlates with increased tissue accumulation of neutrophils exhibiting features of cellular senescence. The loss of effective TRM-mediated clearance is presented as a contributor to organ-level decline during aging.
The prostaglandin E2 receptor EP2 emerged as a regulator of neutrophil clearance by TRMs. The study showed that signaling through EP2 impairs aspects of TRM efferocytosis in aged mice. Genetic deletion of EP2 specifically in TRMs restored their ability to clear senescent neutrophils, indicating that EP2 activity within macrophages is functionally relevant to age-associated defects in efferocytosis.
Mice lacking EP2 expression in TRMs exhibited multiple improvements in age-associated phenotypes. Reported benefits included better spatial memory performance, reductions in markers of skeletal muscle aging, and enhanced cardiac function compared with aged controls. These phenotypic improvements co-occurred with preservation of TRM numbers and augmented phagocytic capacity, and with reduced accumulation of senescent neutrophils across several organs.
Aged TRMs displayed impaired efferocytosis that the authors linked to decreased activation of integrin β2 and suppression of gene programs associated with efferocytosis. These molecular and transcriptional changes limited TRM ability to recognize and engulf senescent neutrophils. EP2 deletion in TRMs was reported to restore integrin β2 activation and re-enable efferocytosis-related transcriptional programs, providing mechanistic insight into how EP2 signaling interferes with macrophage clearance functions during aging.
Beyond genetic manipulation, pharmacologic blockade of EP2 in aged mice reduced the accumulation of senescent neutrophils and reversed features of TRM dysfunction. The study therefore reports concordant effects between genetic deletion and pharmacologic antagonism of EP2, suggesting that EP2 is a tractable target for interventions intended to restore macrophage efferocytosis in aged tissues.
Analysis of human datasets showed age-associated increases in EP2 expression in TRMs. These increases were accompanied by greater accumulation of senescent neutrophils and fewer detected TRM–neutrophil interactions in tissues. These human observations align with the mouse experimental data and support the possibility that EP2-mediated suppression of efferocytosis contributes to human tissue aging. The report presents EP2 targeting as a potential strategy to promote healthier aging through restoration of macrophage clearance function.
The integrated mouse experiments and human data summarized in this report support a model in which impaired macrophage-mediated efferocytosis—driven in part by EP2 signaling—contributes to the accumulation of senescent neutrophils and to organ decline with age. Both TRM-specific EP2 deletion and systemic EP2 antagonism improved neutrophil clearance and mitigated multiple age-related tissue phenotypes in mice. Human dataset analyses showing increased EP2 expression in aged TRMs further suggest translational relevance. Details such as experimental numbers, treatment regimens, and specific quantitative outcomes were reported in the original Science paper; those specifics are not provided in this preview.
Overall, the findings identify EP2 as a candidate target to restore TRM efferocytosis and reduce age-associated tissue dysfunction. Further work would be needed to evaluate safety, dosing, and efficacy of EP2-targeted approaches in humans.